Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (7819)	11/24/1998 8:19:00 PM
From: Bluegreen	Respond to of 17367

Now some of you all might have to help me understand tax benefits. Don't you have to make money by having the possible approval and selling the possible product before worrying about possible taxes? Does this have anything to do with greater of the two possibilities of approval or non approval? What could the prospectus mean to the shareholders if moving domicile to Bermuda was not based on future sales of anticipated possible approval of Neuprex or other possible products? Could one say that whole move of domicile centers around revenue from possible approved products? But wait, doesn't this bring us back to how strongly Xoma might feel about possibility of approval of Neuprex? Does anyone have possible answers or can anyone at least anticipate a possible answer without a change in domicile?